Thus, future therapeutic approaches that can promote increased expression/activation of PKR and phosphorylation of eIF2α may be an effective modality of treatment for breast cancer patients whose breast tumors do not demonstrate elevated PKR. Here, EIF2AK2 is linked to breast carcinoma.